Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy

Daisuke Ennishi, M. Yokoyama, Y. Terui, H. Asai, S. Sakajiri, Y. Mishima, S. Takahashi, H. Komatsu, K. Ikeda, K. Takeuchi, M. Tanimoto, Kiyohiko Hatake

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab. Patients and methods: We retrospectively evaluated the prognostic impact of SIL-2R in 228 DLBCL patients, comparing 141 rituximab-combined CHOP (RCHOP)-treated patients with 87 CHOP-treated patients as a historical control. Results: Patients with high serum SIL-2R showed significantly poorer event-free survival (EFS) and overall survival (OS) than patients with low SIL-2R in both the RCHOP group (2-year EFS, 66% versus 92%, P <0.001; OS, 82% versus 95%, P = 0.005) and the CHOP group (2-year EFS, 40% versus 82%; OS, 61% versus 90%, both P <0.001). Multivariate analysis including the five parameters of International Prognostic Index (IPI) and two-categorized IPI revealed that SIL-2R was an independent prognostic factor for EFS and OS in the RCHOP group as well as in the CHOP group. Conclusions: Our results demonstrate that SIL-2R retains its prognostic value in the rituximab era. The prognostic value of SIL-2R in DLBCL patients receiving rituximab-combined chemotherapy should be reassessed on a larger scale and by long-term follow-up.

Original languageEnglish
Pages (from-to)526-533
Number of pages8
JournalAnnals of Oncology
Volume20
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Interleukin-2 Receptors
Disease-Free Survival
Survival
Therapeutics
Rituximab
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Multivariate Analysis
Drug Therapy
Serum

Keywords

  • Diffuse large B-cell lymphoma
  • Rituximab
  • Soluble interleukin-2 receptor

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. / Ennishi, Daisuke; Yokoyama, M.; Terui, Y.; Asai, H.; Sakajiri, S.; Mishima, Y.; Takahashi, S.; Komatsu, H.; Ikeda, K.; Takeuchi, K.; Tanimoto, M.; Hatake, Kiyohiko.

In: Annals of Oncology, Vol. 20, No. 3, 2009, p. 526-533.

Research output: Contribution to journalArticle

Ennishi, D, Yokoyama, M, Terui, Y, Asai, H, Sakajiri, S, Mishima, Y, Takahashi, S, Komatsu, H, Ikeda, K, Takeuchi, K, Tanimoto, M & Hatake, K 2009, 'Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy', Annals of Oncology, vol. 20, no. 3, pp. 526-533. https://doi.org/10.1093/annonc/mdn677
Ennishi, Daisuke ; Yokoyama, M. ; Terui, Y. ; Asai, H. ; Sakajiri, S. ; Mishima, Y. ; Takahashi, S. ; Komatsu, H. ; Ikeda, K. ; Takeuchi, K. ; Tanimoto, M. ; Hatake, Kiyohiko. / Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. In: Annals of Oncology. 2009 ; Vol. 20, No. 3. pp. 526-533.
@article{c1b09d061efe4bb7a4d297fc5fbf049a,
title = "Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy",
abstract = "Background: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab. Patients and methods: We retrospectively evaluated the prognostic impact of SIL-2R in 228 DLBCL patients, comparing 141 rituximab-combined CHOP (RCHOP)-treated patients with 87 CHOP-treated patients as a historical control. Results: Patients with high serum SIL-2R showed significantly poorer event-free survival (EFS) and overall survival (OS) than patients with low SIL-2R in both the RCHOP group (2-year EFS, 66{\%} versus 92{\%}, P <0.001; OS, 82{\%} versus 95{\%}, P = 0.005) and the CHOP group (2-year EFS, 40{\%} versus 82{\%}; OS, 61{\%} versus 90{\%}, both P <0.001). Multivariate analysis including the five parameters of International Prognostic Index (IPI) and two-categorized IPI revealed that SIL-2R was an independent prognostic factor for EFS and OS in the RCHOP group as well as in the CHOP group. Conclusions: Our results demonstrate that SIL-2R retains its prognostic value in the rituximab era. The prognostic value of SIL-2R in DLBCL patients receiving rituximab-combined chemotherapy should be reassessed on a larger scale and by long-term follow-up.",
keywords = "Diffuse large B-cell lymphoma, Rituximab, Soluble interleukin-2 receptor",
author = "Daisuke Ennishi and M. Yokoyama and Y. Terui and H. Asai and S. Sakajiri and Y. Mishima and S. Takahashi and H. Komatsu and K. Ikeda and K. Takeuchi and M. Tanimoto and Kiyohiko Hatake",
year = "2009",
doi = "10.1093/annonc/mdn677",
language = "English",
volume = "20",
pages = "526--533",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy

AU - Ennishi, Daisuke

AU - Yokoyama, M.

AU - Terui, Y.

AU - Asai, H.

AU - Sakajiri, S.

AU - Mishima, Y.

AU - Takahashi, S.

AU - Komatsu, H.

AU - Ikeda, K.

AU - Takeuchi, K.

AU - Tanimoto, M.

AU - Hatake, Kiyohiko

PY - 2009

Y1 - 2009

N2 - Background: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab. Patients and methods: We retrospectively evaluated the prognostic impact of SIL-2R in 228 DLBCL patients, comparing 141 rituximab-combined CHOP (RCHOP)-treated patients with 87 CHOP-treated patients as a historical control. Results: Patients with high serum SIL-2R showed significantly poorer event-free survival (EFS) and overall survival (OS) than patients with low SIL-2R in both the RCHOP group (2-year EFS, 66% versus 92%, P <0.001; OS, 82% versus 95%, P = 0.005) and the CHOP group (2-year EFS, 40% versus 82%; OS, 61% versus 90%, both P <0.001). Multivariate analysis including the five parameters of International Prognostic Index (IPI) and two-categorized IPI revealed that SIL-2R was an independent prognostic factor for EFS and OS in the RCHOP group as well as in the CHOP group. Conclusions: Our results demonstrate that SIL-2R retains its prognostic value in the rituximab era. The prognostic value of SIL-2R in DLBCL patients receiving rituximab-combined chemotherapy should be reassessed on a larger scale and by long-term follow-up.

AB - Background: Soluble interleukin-2 receptor (SIL-2R) is known to be a prognostic parameter in patients with diffuse large B-cell lymphoma (DLBCL) receiving cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy. However, its prognostic value has not been well known since the introduction of rituximab. Patients and methods: We retrospectively evaluated the prognostic impact of SIL-2R in 228 DLBCL patients, comparing 141 rituximab-combined CHOP (RCHOP)-treated patients with 87 CHOP-treated patients as a historical control. Results: Patients with high serum SIL-2R showed significantly poorer event-free survival (EFS) and overall survival (OS) than patients with low SIL-2R in both the RCHOP group (2-year EFS, 66% versus 92%, P <0.001; OS, 82% versus 95%, P = 0.005) and the CHOP group (2-year EFS, 40% versus 82%; OS, 61% versus 90%, both P <0.001). Multivariate analysis including the five parameters of International Prognostic Index (IPI) and two-categorized IPI revealed that SIL-2R was an independent prognostic factor for EFS and OS in the RCHOP group as well as in the CHOP group. Conclusions: Our results demonstrate that SIL-2R retains its prognostic value in the rituximab era. The prognostic value of SIL-2R in DLBCL patients receiving rituximab-combined chemotherapy should be reassessed on a larger scale and by long-term follow-up.

KW - Diffuse large B-cell lymphoma

KW - Rituximab

KW - Soluble interleukin-2 receptor

UR - http://www.scopus.com/inward/record.url?scp=61649088127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649088127&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn677

DO - 10.1093/annonc/mdn677

M3 - Article

VL - 20

SP - 526

EP - 533

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -